Updated 2 October 2026 · Aurelis Peptides
Tesamorelin is best known for research on excess abdominal fat. It stimulates the body’s own growth hormone release. Human studies have investigated fat around internal organs and fat in the liver, particularly in adults with HIV.
That specific population is an important part of the findings.
| Main interest | Excess abdominal fat and related metabolic research |
|---|---|
| What studies looked at | Fat around internal organs and liver fat |
| Study context | Human studies in defined HIV-associated populations |
| Listed content | 5 mg / 10 mg per unit |
What fat-reduction benefits were measured?
- A six-month trial found reductions in fat around internal organs and liver fat in adults with HIV and abdominal fat accumulation.
- A separate study found reduced liver-fat levels in people with HIV and fatty liver disease.
- The results were measured against placebo in those selected groups.
Abdominal- and liver-fat study · Fatty-liver study.
How does tesamorelin work?
Tesamorelin acts like the body’s growth-hormone-releasing signal, encouraging the pituitary to release growth hormone. Egrifta WR, a specific tesamorelin medicine, is approved for excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight-loss management. The Aurelis entry is a separate research material. See the medicine information.
For broader weight-management research, our Retatrutide and Tirzepatide guides cover different peptide pathways.
Explore the catalogue entries
Aurelis lists Tesamorelin 5 mg and 10 mg content per unit. Choose the entry that matches your enquiry and ask about the presentation and batch documents.
Explore Tesamorelin with Aurelis
Contact our team about Tesamorelin 5 mg or 10 mg, local availability and available product records.
Aurelis holds stock in Australia, Canada and the USA. Tell us your destination so our team can check local availability.
Enquire about Tesamorelin · Open the Tesamorelin catalogue profile